Your key to access the most innovative specialty drugs.
Specialty Drug Access
Specialty drugs are at the forefront of medical research and innovation. Often developed to address orphan diseases and chronic illnesses, specialty drugs provide hope for patients with otherwise untreatable conditions.
In 2025, the US FDA approved 46 novel drugs majority specialty and /or orphan drugs,
Almost one third of these are new oncology treatments.
Specialty drugs are often discovered and manufactured by small biotechnology companies making them almost inaccessible to the Middle East.
MEHA Solutions brings specialty drugs to you. Our focus is on orphan or rare-disease, oncology, neurology, and rheumatology drugs.
Through our deep knowledge of the pharmaceutical supply chain and our strong relationships with manufacturers, large and small, we facilitate connecting emerging manufacturers to partners in the Middle East in order to expand patient access to the region.
Expand your distribution to untapped markets.
Commercialization
We know it’s difficult to gain market access to the Middle East without a large sales force or previous experience in the region. That’s why the MEHA Solutions team has healthcare professionals based in both the U.S. and the Middle East.
Our familiarity with both healthcare systems will simplify the process of shipping your products to care providers throughout the Middle East.